BRCA surveillance versus risk-reducing mastectomy, KEYNOTE-522, and when Oncotype would spare chemo
Medical oncology slice of a Gold Coast breast-cancer CPD: germline BRCA choices after a June 2026 JCO cohort, neoadjuvant immunotherapy for triple-negative disease, adjuvant chemo generations, PREDICT and Oncotype, and whether chemo spoils immediate reconstruction.
- Speaker 1 — unnamed medical oncologist
- Otter never names this clinician. Do not invent a name. Recording opens mid-sentence on hereditary risk percentages, then covers BRCA surveillance versus risk-reducing mastectomy, prognostic variables, KEYNOTE-522, adjuvant chemo and endocrine therapy, PREDICT, Oncotype DX, and a 2021 reconstruction-complication cohort. Ends by thanking the room and taking questions before the next speaker is introduced.
- Next speaker (not covered here)
- Dr Tom Hung — radiologist / nuclear medicine, oncological imaging interest. Same-day talk already published at breast-imaging.drkotha.com.
Educational summary of one Wednesday 10 June 2026 medical oncology CPD talk on the Gold Coast (Otter title: “Breast Cancer Treatment Overview”; otter_id n_ib7EMQyxNWU3ty8IzJI6dGPsg). About 20 minutes were captured; the recording starts mid-sentence. This is not personal medical advice. Check current PBS criteria, Medicare MRI items, PREDICT outputs, Oncotype / EndoPredict funding, KEYNOTE-522 eligibility, and TGA product information before changing practice.
Otter.ai garbles BRCA, “virus-producing mastectomy” (risk-reducing), KEYNOTE-522 (Keno 522), pembrolizumab / Keytruda (kembrolizumab / Ketruda), PREDICT (“Project Breast Cancer”), CDK4/6 (“CE four six”), Ki-67 (“Key 67” / “Q 67”), doxorubicin (“Adrianmyson”), pegfilgrastim (“lipid frogasten”), nodal status (“noble”), axilla (“absorber”), and Medicare MRI age (“up to the age of 16” — almost certainly 60). Where the recording is unclear, this page says what Otter said rather than silently fixing numbers.
Genetics opening — and the Otter reverse
The recording starts mid-sentence. Otter captured: breast cancers “account for 70–80% hereditary, 5–10% familial, around 15–20% more to do with low-penetrance genes.”
Standard teaching is the opposite: most breast cancer is sporadic (~70–80%), with a smaller hereditary high-penetrance slice and a familial / low-penetrance remainder. Treat Otter’s opening percentages as a transcription garble, not as a new epidemiology fact. The speaker then moved quickly to variant classification, which is clearer.
Databases in this space are more mature than they used to be. Pathogenic variants you act on are class 4 and 5. Classes 1, 2, and 3 are largely ignored — “scarring mistakes.” Everyone carries a certain number of those lower-class findings.
JCO April 2026: BRCA surveillance versus risk-reducing mastectomy
An observational cohort in the Journal of Clinical Oncology, April 2026, compared bilateral risk-reducing mastectomy (RRM) with active surveillance under current guidelines. About 1,200 asymptomatic women with BRCA1 or BRCA2 pathogenic variants. Speaker noted the usual observational caveats.
- 62% stayed on surveillance; 38% had risk-reducing mastectomy (Otter: “virus-producing mastectomy”).
- BRCA1 carriers were more likely to choose mastectomy — 44% versus 33% — framed as informed choice around BRCA1’s triple-negative risk.
- Breast-cancer incidence: 14.5% on surveillance versus 1.5% after RRM.
- Of 105 surveillance women who developed breast cancer, about half later had risk-reducing mastectomy.
- After RRM, annual incidence ~0.15%; overall about a 95% incidence reduction after adjustment.
- Breast-cancer-specific survival showed no overall difference — credited to intense modern screening, especially MRI.
MRI, mortality, and the Medicare age garble
MRI in a BRCA1/BRCA2 germline setting was cited with a breast-cancer mortality hazard ratio of 0.2 (about an 80% mortality reduction in that framing). The practical message: informed patients who are strongly averse to mastectomy can reasonably stay on vigilant surveillance — with eyes open.
On Medicare-funded annual MRI, Otter transcribed: “up to the age of 16.” That is almost certainly a mis-hear of 60. This page records what Otter said and does not treat age 16 as a protocol. Confirm the current Medicare MRI item age criteria yourself.
Caution on BRCA1 surveillance
Even when surveillance finds a tiny cancer in a BRCA1 carrier, that cancer is more often triple negative. That pushes the patient toward chemotherapy — neoadjuvant or adjuvant — so “avoiding mastectomy” does not always mean avoiding systemic treatment intensity.
Prognostic variables and subtypes
Variables used to prognosticate and decide systemic therapy:
- Tumour size
- Nodal status (Otter: “noble status”)
- Grade
- How strongly hormone receptor–positive the tumour is (strongly positive disease behaves more predictably)
- HER2 overexpression (raises risk)
- Lymphovascular invasion (LVI)
- Proliferative markers such as Ki-67 (Otter: “Key 67” / “Q 67”)
Subtype → treatment path
- HER2-positive and triple-negative: often think neoadjuvant (then adjuvant) if tumour >20 mm or any node involved.
- Hormone-positive: tease luminal A versus luminal B. Luminal B is a bit more aggressive / higher Ki-67. Panels such as Oncotype help decide whether adjuvant chemo is actually indicated.
Why neoadjuvant — and KEYNOTE-522
Benefits of neoadjuvant chemotherapy the speaker listed:
- Downstage the breast and axilla (Otter: “absorber”) — potentially less surgery.
- Assess response: residual disease versus pathological complete response (pCR) at operation.
- If residual disease in triple-negative disease, further adjuvant options after surgery; analogous HER2-positive pathways with different drugs.
- Time to genetic counselling and fast-track germline testing so surgeons can plan definitive surgery if a BRCA (Otter: “breakup”) mutation is found.
KEYNOTE-522 (Otter: Keno 522)
Landmark neoadjuvant trial in triple-negative breast cancer: chemotherapy plus pembrolizumab (Keytruda; Otter: “kembrolizumab” / “Ketruda”) versus chemo plus placebo.
Otter said pathological complete response was 64.8% in “those patients who really didn’t have the pembrolizumab.” That contradicts the trial framing (pembrolizumab arm is the higher pCR arm). Quote Otter; do not invent which arm actually hit 64.8% from memory on this page — check the published KEYNOTE-522 figures and the seven-year update yourself.
Event-free survival benefit was highlighted. A seven-year ASCO update about a week before this talk maintained significant hazard ratios for event-free survival and overall survival.
Adjuvant chemo generations, G-CSF bone pain, endocrine and CDK4/6
| Regime idea | Typical use (as framed) | Notes from the talk |
|---|---|---|
| 2nd generation — TC (taxane + cyclophosphamide) | Often node-negative | Otter: “taxeter”. Four cycles often referenced in this framing. |
| 3rd generation — adds anthracycline / doxorubicin | More node-positive | Otter: “Adrianmyson”. Secondary leukaemia; cardiotoxicity especially into the 70s. |
Long-acting G-CSF on day 2 (Otter: “lipid frogasten” = pegfilgrastim / lipegfilgrastim) reduces neutropenic infection risk. First-dose bone pain is very common — warn GPs seeing patients the day after their first injection; it usually settles, and the second cycle is milder. Simple analgesia. Compared with a New Zealand era when long-acting G-CSF was not funded, adjuvant chemo is now much safer from a neutropenic-sepsis ward perspective.
Endocrine and add-ons
- Tamoxifen; aromatase inhibitors a bit better (Otter: “rhomatizing”).
- Ovarian suppression in high-risk premenopausal women.
- Consider extending adjuvant endocrine therapy.
- Bisphosphonates: bone health plus a slight recurrence-risk reduction.
- CDK4/6 inhibitors when criteria are met (Otter: “CE four six if it is two”).
PREDICT and Oncotype DX — still not Medicare-funded
PREDICT (Otter: “Project Breast Cancer”) is open-source. Enter size, grade, and related details; compare extra overall-survival benefit from 2nd-gen chemo, 3rd-gen chemo, and endocrine therapy. Useful to show patients so they can “get their head around” absolute benefit.
Oncotype DX remains the most validated panel for chemo benefit in HR+ disease. Speaker’s frustration: still not Medicare-funded. EndoPredict is partially funded. RxPONDER: low recurrence score → no chemo benefit demonstrated — many patients avoid chemotherapy because of this kind of panel.
2021 reconstruction cohort: does chemo spoil the implant?
2021 multi-site cohort (11 US/Canada sites), ~1,800 women, immediate implant-based versus autologous reconstruction. Chart review for any / major complications (hospitalisation or reoperation) plus BREAST-Q patient-reported outcomes (satisfaction, psychosocial, physical, sexual wellbeing).
- Immediate implant 73% vs autologous 27%.
- Chemo: 10% neoadjuvant, 35% adjuvant, 53% none.
- Chemo groups much more likely to get radiotherapy: 54% / 48% versus 14% with no chemo.
- No-chemo patients tended to be older — adjusted in analysis.
Implant any-complication rates
- Adjuvant chemo: 31%
- Neoadjuvant: 28%
- No chemo: 24%
After adjustment, differences were not statistically significant; adjuvant was bordering on significance. Autologous reconstruction: no significant difference by chemo group. PROs mostly similar after adjustment; sexual wellbeing reduced in implant + chemo groups. Conclusion stated: neoadjuvant and adjuvant therapy did not significantly increase complication rates or patient dissatisfaction, and did not impair overall psychological wellbeing.
Practical timing, phone-a-friend, early antibiotics
- Wait at least four weeks after reconstruction before starting adjuvant chemo; longer if wound healing is poor — watch the wound closely.
- For third-generation regimens, sometimes start the taxane before AC if timing / healing needs juggling.
- Long-acting G-CSF made adjuvant chemo safer versus the older NZ neutropenic-sepsis picture.
- Patients should know they can always phone the oncology team; institute early antibiotics for infection signs.
Q&A: immunotherapy is a TN story for now
Floor question on immunotherapy lines. Speaker’s answer: look at how immunogenic the cancer is. Current data in this setting sit with triple-negative disease (pembrolizumab / Keytruda). No data yet to use immunotherapy routinely in HER2-positive or luminal disease in this framing. Personalised mRNA vaccines are moving in lung and melanoma; speaker expects combination immunotherapy-plus-personalised approaches in breast cancer within a few years.
Session closed; the chair introduced Dr Tom Hung for the imaging talk — see the companion page.
Take-home messages for clinic
- BRCA RRM cuts incidence ~95% in that observational cohort; survival may not separate if MRI surveillance is excellent — counsel both ways.
- BRCA1 surveillance still often means chemo if a small TN cancer appears.
- Neoadjuvant for HER2+ / TN above size or node thresholds buys downstaging, response assessment, and germline-testing time.
- KEYNOTE-522-style pembrolizumab + chemo is the TN neoadjuvant story; check the published pCR arm and the 7-year OS/EFS update.
- Warn about day-2 long-acting G-CSF bone pain on cycle one.
- Use PREDICT with patients; Oncotype remains best validated for chemo benefit but is still not Medicare-funded.
- Chemo did not clearly wreck reconstruction outcomes after adjustment — still wait ≥4 weeks, mind the wound, phone early.
Imaging half of this breast-cancer CPD evening: breast-imaging.drkotha.com (Dr Tom Hung and colleagues).
drkotha.com · CPD lecture summary · denim theme · breast-treatment.drkotha.com